PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Analysis

PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Analysis

  • Products Id :- GDHC014PSR
  • |
  • Pages: 101
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Analysis

GlobalData's "PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Analysis" report is an essential source of information and analysis on the gene therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends analysis, GlobalData provides an in-depth analysis of the current and future growth drivers of the gene therapy market. The report discusses the key factors shaping and driving the gene therapy business, and provides insights on the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of gene therapies.


Key Questions Answered

What are the drivers of the gene therapy field?

Who are the leading companies involved in the development of gene therapies?

What are the major trends in gene therapy clinical trials?

What specific therapeutic areas and indications are receiving the most clinical research?

What progress has been made in terms of viral vector technology and gene delivery?

What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)?

Has investor confidence been restored in the gene therapy field?


This report provides market developments across the gene therapy field, including clinical trials, deals, and pipeline investments

Investment examined on both the industry and financial communities

Broad discussion on the science behind gene therapies, viral vectors, and gene delivery

Clinical trials activity examined across phase of development, therapy area, and indication.

This report offers a deep dive into the synergies behind partnering and acquisition activity

Deals activity examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action

Pipeline profiles of 20 leading biotech companies developing gene therapies

Reasons To Buy

Identify the key players in the gene therapy market

Analyze and track the strategies that companies are using to strengthen their position in the gene therapy field; independent source for due diligence

Organize your sales and marketing strategy to identify companies with proprietary technologies in order to maximize opportunities for licensing, partnership, investment, or takeover

Understand the flow of investment from capital markets into the gene therapy field

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


1 Table of Contents

1 Table of Contents 6

1.1 List of Tables 9

1.2 List of Figures 10

2 Introduction 12

2.1 Report Scope 12

2.2 Companies Mentioned 13

2.3 Upcoming Reports 13

2.4 Recently Published Reports 13

3 Gene Therapy Overview 14

3.1 What is Gene Therapy? 14

3.2 Gene Delivery 16

3.2.1 Viral Vectors 17

3.2.2 Non-Viral Vectors and Naked DNA 21

4 Market Developments 22

4.1 Turning Point: Glybera Approval 23

4.2 GSK Files Application to the EMA for Gene Therapy for ADA-SCID 24

4.3 Celladon's Reports Negative Results for Mydicar in Advanced Heart Failure 25

4.4 Spark Initiates Phase I/II Clinical Trial of SPK-CHM for Choroideremia 26

4.5 FDA Accepts Sangamo's IND to Begin Trial of Gene Therapy for Beta-Thalassemia 26

4.6 Paying for Gene Therapies: Annuity Model 27

5 Clinical Trials 29

5.1 Overview 29

5.2 Company 31

5.3 Phase of Development 32

5.4 Therapy Area 33

5.5 Indication 35

5.6 Investigators 36

5.6.1 Specialty 36

5.6.2 Country 38

6 Company Analysis 39

6.1 Overview 39

6.1.1 Entity Type 39

6.1.2 Regional Split 39

6.2 Financial Highlights 40

6.2.1 Revenue 41

6.2.2 R&D Spending 42

6.2.3 Market Capitalization 43

6.2.4 Stock Performance 45

6.3 Pipeline Profiles 46

6.3.1 Advantagene 47

6.3.2 ALS Therapy Development Institute 48

6.3.3 Amarna Therapeutics 49

6.3.4 American Gene Technologies International 50

6.3.5 AnGes MG 51

6.3.6 Applied Genetic Technologies Corporation 54

6.3.7 Asklepios BioPharmaceutical 55

6.3.8 Avalanche Biotechnologies 56

6.3.9 Bluebird bio 58

6.3.10 Celladon 60

6.3.11 Dimension Therapeutics 61

6.3.12 GeneCure Biotechnologies 62

6.3.13 Genethon 63

6.3.14 GenSight Biologics 63

6.3.15 Oxford BioMedica 64

6.3.16 ReGenX Biosciences 66

6.3.17 Sangamo BioSciences 67

6.3.18 Spark Therapeutics 70

6.3.19 UniQure 71

6.3.20 Voyager Therapeutics 74

7 Deals Landscape 75

7.1 Overview 75

7.1.1 Geography 77

7.1.2 Entity Type 79

7.1.3 Company 80

7.1.4 Stage 81

7.1.5 Therapy Area 82

7.1.6 Indication 84

7.1.7 Mechanism of Action 86

7.2 Deal Type 86

7.2.1 Mergers and Acquisitions 87

7.2.2 Licensing and Partnerships 89

7.2.3 Capital Raisings 92

8 Strategic Outlook 95

9 Appendix 96

9.1 Bibliography 96

9.2 Research Methodology 96

9.2.1 Coverage 96

9.2.2 Secondary Research 97

9.3 About the Author 98

9.3.1 Adam Dion, Senior Industry Analyst 98

9.4 Global Head of Healthcare 99

9.5 About the Industry Dynamics Team 99

9.6 About GlobalData 100

9.7 Disclosure Information 100

9.8 Disclaimer 100

1.2 List of Figures

Figure 1: Number of Gene Therapy Clinical Trials, 2009-2014 29

Figure 2: Number of Gene Therapy Clinical Trials by Indication and Stage 31

Figure 3: Gene Therapy Clinical Trials by Company 32

Figure 4: Gene Therapy Clinical Trials by Phase of Development 33

Figure 5: Gene Therapy Clinical Trials by Therapy Area 34

Figure 6: Gene Therapy Clinical Trials, Percentage by Therapy Area 35

Figure 7: Gene Therapy Clinical Trials, Top Indications 36

Figure 8: Investigators by Specialty, Gene Therapy 37

Figure 9: Investigators by Country, Gene Therapy 38

Figure 10: Gene Therapy Companies, Entity Type 39

Figure 11: Gene Therapy Companies, Regional Split 40

Figure 12: Gene Therapy Companies by Revenue (USD m), 2013 42

Figure 13: Gene Therapy Companies by R&D Spending (USD m), 2013 43

Figure 14: Gene Therapy Companies by Market Capitalization (USD m) 44

Figure 15: Leading Gene Therapy Companies, Stock Performance (USD USD) 46

Figure 16: Gene Therapy Deals, Total Number of Deals and Deal Values (USD m), 2009-2015 76

Figure 17: Gene Therapy Deals, Deal Value (USD m) by DealType, 2014 77

Figure 18: Gene Therapy Deals, Number of Deals and Deal Values (USD m) by Region, 2009-2015 78

Figure 19: Gene Therapy Deals by Region, 2009-2015 78

Figure 20: Gene Therapy Deals by Region, Deal Value (USD m), 2009-2015 79

Figure 21: Gene Therapy Deals by Entity Type, Private vs. Public, 2009-2015 79

Figure 22: Gene Therapy Deals, Number of Deals and Deal Values (USD m) by Company, 2009-2015 80

Figure 23: Gene Therapy Deals, Number of Deals and Deal Values (USD m), by Product Stage, 2009-2015 82

Figure 24: Gene Therapy Deals, Number of Deals and Deal Values (USD m), by Therapy Area, 2009-2015 83

Figure 25: Gene Therapy Deals by Indication, (>USD 500m), 2009-2015 84

Figure 26: Gene Therapy Deals by Indication, (

Figure 27: Gene Therapy Deals, Number of Deals and Deal Values (USD m) by Mechanism of Action, 2009-2015 86

Figure 28: Gene Therapy Deals, Number of M&A Deals and Deal Values (USD m), 2010-2015 87

Figure 29: Gene Therapy, Number of Licensing Deals and Deal Values (USD m), 2009-2015 89

Figure 30: Gene Therapy, Number of Capital Raisings and Deal Values (USD m), 2009-2015 92

Figure 31: Gene Therapy, Number of Capital Raisings by Financial Advisor, 2009-2015 93

1.1 List of Tables

Table 1: Common Diseases for Gene Therapy, Defects and Target Cells 15

Table 2: Main Groups of Viral Vectors and Their Characteristics 19

Table 3: Advantagene 48

Table 4: ALS Therapy Development Institute 49

Table 5: Amarna Therapeutics 50

Table 6: American Gene Technologies International 51

Table 7: AnGes MG 53

Table 8: Applied Genetic Technologies Corporation 55

Table 9: Asklepios BioPharmaceutical 56

Table 10: Avalanche Biotechnologies 57

Table 11: Bluebird bio 59

Table 12: Celladon 61

Table 13: Dimension Therapeutics 62

Table 14: GeneCure Biotechnologies 62

Table 15: Genethon 63

Table 16: GenSight Biologics 64

Table 17: Oxford BioMedica 65

Table 18: ReGenX Biosciences 66

Table 19: Sangamo BioSciences 69

Table 20: Spark Therapeutics 71

Table 21: UniQure 73

Table 22: Voyager Therapeutics 74

Table 23: Gene Therapy, M&A Deals Table Summary, 2010-2014 88

Table 24: Gene Therapy, Licensing Deals Table Summary, 2009-2015 90

Table 25: Gene Therapy, Capital Raisings Table Summary, 2013-2015 94

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]


ALS Therapy Development Institute

Amarna Therapeutics

American Gene Technologies

AnGes MG

Applied Genetic Technologies International

Asklepios BioPharmaceutical

Avalanche Biotechnologies

Benitec BioPharma

Bluebird bio



CFR Pharmaceuticals

Chiesi Farmaceutici

Dimension Therapeutics

GeneCure Biotechnologies


GenSight Biologics


Oxford BioMedica


ReGenX Biosciences

Sangamo BioSciences

Spark Therapeutics

Tacere Therapeutics



Voyager Therapeutics

select a license

Single User License
USD 2995 INR 215281
Site License
USD 5990 INR 430561
Corporate User License
USD 8985 INR 645842



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]